Cullinan Pearl

In conjunction with Taiho Pharmaceuticals, Cullinan Pearl is developing CLN-081, an orally available tyrosine kinase inhibitor designed to target EGFR (Epidermal Growth Factor Receptor) exon 20 mutations. Cullinan was intrigued with the selectivity index of this molecule across a range of biochemical and in vitro assays; namely the molecule’s ability to inhibit EGFR variants with exon 20 mutations while sparing wild-type EGFR.

Poster Presentations

2021 ASCO

Poster – Abstract 9077: Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20)

Poster - Cullinan Abstract 9077: Safety and activity of CLN-081

2020 ESMO

Poster – Preliminary Safety and Activity of CLN-081 in NSCLC with EGFR Exon 20 Insertion Mutations (Ins20)

Poster – Preliminary Safety and Activity of CLN-081

2019 WCLC

Poster – Multicenter Phase 1/2a trial of CLN-081 (TAS6417) in NSCLC Patients with EGFR Exon 20 Insertion Mutations

Cullinan Pearl Safety Poster